This course includes:
Longevity medicine is a fast-evolving field and it is currently outpacing the ability of the medical practice to internalize and implement the progress of related research. Modern advances in AI and machine learning, biomarker research and drug development have produced numerous tools for early diagnostics and prevention, which remain unknown to the global medical community. The paradigm of longevity and healthy aging as the top priority will undoubtedly greatly impact the primary, secondary and tertiary prevention rates. The Longevity Medicine Course (LMC) is a pivotal curriculum that provides medical professionals with most recent advances in biogerontology, geroscience and precision medicine, while teaching the ways to implement this knowledge in the clinical practice. The curriculum has been developed by interdisciplinary experts (physicians, academic biogerontologists, AI-experts, computer scientists, KOL in longevity), covering the necessary foundation and most recent scientific evidence. Here, you can find the Introduction to Longevity Medicine – the first part of the LMC, equipping with core definitions, clinical applications of recent advances in aging research, skills to evaluate the validity of biomarkers of aging and other biological age testing systems and knowledge of the available longevity therapies to tackle aging and age-related diseases, which are mostly based on senescence-related processes in the organisms. At the same time, we explore areas of non-clinical medical applications, which are largely unknown by physicians.
Within 48h successful completion of this course, the instructor will send a personalised message to your Udemy account and email address with details of how to access your exclusive certificate from the Deep Longevity Team. Be sure to check back into your account within this time to access your certificate.
Who this course is for:
5 sections - 17 lectures - 03:20:25 total length
People Also Search
Students Also Bought
Alex Zhavoronkov, PhD, is the founder and CEO of Deep Longevity, Inc, a global company developing a broad range of artificial intelligence-based biomarkers of aging and longevity. He is also the founder and CEO of Insilico Medicine, a leader in next-generation artificial intelligence technologies for drug discovery, and biomarker development. Since 2015 he has invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership Insilico raised over $50 million in multiple rounds from expert investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Prior to founding Insilico, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, Biogerontology Research Foundation. Since 2012 he published over 130 peer-reviewed research papers, and 2 books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). He serves on the editorial boards of Aging Research Reviews, Aging, Trends in Molecular Medicine, Frontiers in Genetics, and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (7th annual in 2020) at Basel Life, one of Europe's largest industry events in drug discovery. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.